Using machine learning for mortality prediction and risk stratification in atezolizumab‐treated cancer patients: Integrative analysis of eight clinical trials-Reference-Cited by-同舟云学术

Using machine learning for mortality prediction and risk stratification in atezolizumab‐treated cancer patients: Integrative analysis of eight clinical trials

Published:2022-07-24 Issue:3 Volume:12 Page:3744-3757
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Wu Yougen¹^ORCID,Zhu Wenyu²,Wang Jing²,Liu Lvwen²,Zhang Wei³,Wang Yang⁴,Shi Jindong⁵,Xia Ju¹,Gu Yuting¹,Qian Qingqing¹⁶^ORCID,Hong Yang¹⁷^ORCID

Affiliation:

1. National Institute of Clinical Research, The Fifth People's Hospital of Shanghai Fudan University Shanghai China

2. Shanghai Long For Health Data Technology Co.ltd Shanghai China

3. Department of Biostatistics Fudan University School of Public Health Shanghai China

4. Department of Urology The Fifth People's Hospital of Shanghai, Fudan University Shanghai China

5. Department of Respiratory Medicine The Fifth People's Hospital of Shanghai, Fudan University Shanghai China

6. Department of Pharmacy, The Fifth People's Hospital of Shanghai Fudan University Shanghai China

7. Department of Osteology, The Fifth People's Hospital of Shanghai Fudan University Shanghai China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5060

Reference33 articles.

1. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

2. Atezolizumab is approved to treat hepatocellular carcinoma melanoma non‐small cell lung cancer and small cell lung cancer.https://www.cancer.gov/about‐cancer/treatment/drugs/atezolizumab. Accessed July 22 2022.

3. FDA approves atezolizumab for PD‐L1 positive unresectable locally advanced or metastatic triple‐negative breast cancer.https://www.fda.gov/drugs/drug‐approvals‐and‐databases/fda‐approves‐atezolizumab‐pd‐l1‐positive‐unresectable‐locally‐advanced‐or‐metastatic‐triple‐negative. Accessed July 22 2022.

4. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A deep learning approach for overall survival prediction in lung cancer with missing values;Computer Methods and Programs in Biomedicine;2024-09

2. Prognostic model development and clinical correlation of eight key genes in skin cutaneous melanoma;Heliyon;2024-07

3. Mining novel biomarkers for prognosis of skin cutaneous melanoma with proteomic analysis;2024-03-08

4. Just how transformative will AI/ML be for immuno-oncology?;Journal for ImmunoTherapy of Cancer;2024-03

5. Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data;JCO Clinical Cancer Informatics;2024-03